← Back to Search

Prostacyclin Analogue

Iloprost for Lung Cancer Prevention

Phase 1
Waitlist Available
Led By York E Miller
Research Sponsored by National Cancer Institute (NCI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must have a smoking history of 20 pack-years or greater
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will compare the effects of inhaled iloprost to a placebo in preventing lung cancer in former smokers.

Eligible Conditions
  • Lung Cancer

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
You must have smoked the equivalent of 20 packs of cigarettes per year or more.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Incidence of clinical toxicity
Anesthetics, Inhalation
Secondary outcome measures
Endobronchial brushing gene expression
Gene expression of dysplastic lesions
Chronic Obstructive Airway Disease
+3 more

Side effects data

From 2009 Phase 2 trial • 152 Patients • NCT00084409
53%
Headache
24%
Flushing
17%
Myalgia (muscle pain)
16%
Nausea
16%
Pain - Other
11%
Fatigue
9%
Neuropathic pain
4%
Hospitalization
4%
Metabolic/Laboratory - Other
100%
80%
60%
40%
20%
0%
Study treatment Arm
Placebo
Iloprost

Trial Design

4Treatment groups
Experimental Treatment
Placebo Group
Group I: Arm III (iloprost BID)Experimental Treatment3 Interventions
Patients receive iloprost via inhalation using a nebulizer BID for 60 days.
Group II: Arm I (iloprost QID)Experimental Treatment3 Interventions
Patients receive iloprost via inhalation using a nebulizer QID for 60 days.
Group III: Arm II (placebo QID)Placebo Group3 Interventions
Patients receive placebo via inhalation using a nebulizer QID for 60 days.
Group IV: Arm IV (placebo BID)Placebo Group3 Interventions
Patients receive placebo via inhalation using a nebulizer BID for 60 days.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Iloprost
2010
Completed Phase 4
~1180

Find a Location

Who is running the clinical trial?

National Cancer Institute (NCI)Lead Sponsor
13,603 Previous Clinical Trials
40,913,241 Total Patients Enrolled
York E MillerPrincipal InvestigatorNorthwestern University
1 Previous Clinical Trials
80 Total Patients Enrolled

Media Library

Iloprost (Prostacyclin Analogue) Clinical Trial Eligibility Overview. Trial Name: NCT02237183 — Phase 1
Lung Cancer Research Study Groups: Arm I (iloprost QID), Arm II (placebo QID), Arm III (iloprost BID), Arm IV (placebo BID)
Lung Cancer Clinical Trial 2023: Iloprost Highlights & Side Effects. Trial Name: NCT02237183 — Phase 1
Iloprost (Prostacyclin Analogue) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02237183 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the primary aims of this experimental research?

"This clinical trial, to be assessed over a two-month period, has the goal of measuring incidents of toxicity. Secondary endpoints are whether in vitro responses from cultured airway epithelial progenitor cells can predict iloprost's efficacy; descriptive statistics regarding dysplastic lesion gene expression and endobronchial brushing gene expression focusing on prostacyclin pathways."

Answered by AI

Is it possible to enroll in this experiment at present?

"Per the clinicaltrials.gov website, this experiment is not presently seeking participants. It was first publicized on November 5th 2015 and last revised on June 28th 2022. However, 1510 other trials remain open to enrollment at present."

Answered by AI

What is the uppermost capacity of participants in this research endeavor?

"Currently, this trial is not accepting new enrollees. It was initially established on November 5th 2015 and last updated June 28th 2022. If you are seeking other research opportunities, 1504 studies for lung carcinoma and 6 trials utilizing Iloprost have open recruitment periods currently."

Answered by AI

Is it possible for me to join this scientific experiment?

"In order to meet the criteria of this trial, contenders must possess lung carcinoma and be aged between 18-85. Currently, 34 participants are being sought out for the study."

Answered by AI

Has Iloprost received the necessary regulatory clearance from the FDA?

"Iloprost's safety is still largely unknown, with limited clinical data to support efficacy. Our evaluation team at Power thus assigned it a score of 1."

Answered by AI

Is this research accommodating participants aged above seventy-five?

"This research programme is looking for volunteers aged 18 and above, but no older than 85."

Answered by AI
~4 spots leftby Mar 2025